君實生物(01877.HK)終止與阿斯利康推廣合作 收回注射液「拓益」推廣權
君實生物(01877.HK)(688180.SH)公布,隨著公司自建的商業化團隊逐步成熟,特瑞普利單抗注射液(「拓益」)更多適應症成功納入最新版國家醫保目錄,為更好地落實下一發展階段的產品商業化推廣策略,積極應對未來的市場競爭格局,經友好協商,與阿斯利康製藥簽署《獨家推廣協議終止協議》,自2022年1月1日起收回原協議約定的拓益推廣權。
公司於去年2月28日與阿斯利康簽署《獨家推廣協議》,向阿斯利康製藥授出拓益在中國大陸地區後續獲批上市的泌尿腫瘤領域適應症的獨家推廣權,及所有獲批適應症在非核心城市區域的獨家推廣權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.